PHASE II STUDY OF MONOCLONAL ANTIBODY 17-1A WITH GM-CSF IN TREATMENT OF 5-FU RESISTANT COLORECTAL CANCER
OBJECTIVES: I. Assess the response rate, duration of response, and survival after treatment
with monoclonal antibody 17-1A and granulocyte-macrophage colony stimulating factor in
patients with colorectal cancer metastatic to nonhepatic sites and refractory to
fluorouracil. II. Describe the toxicities associated with this regimen. III. Assess the
quality of life in these patients.
OUTLINE: Biological Response Modifier Therapy. Colorectal antigen 17-1A murine monoclonal
antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor
(Immunex), GM-CSF, NSC-613795.
PROJECTED ACCRUAL: There will be 30 evaluable patients accrued into this study over
approximately 1 year.
Primary Purpose: Treatment
James D. Ahlgren, MD
George Washington University
United States: Federal Government
|George Washington University Hospital||Washington, District of Columbia 20037|